John Lee
2018 - PhaseBio Pharmaceuticals
In 2018, John Lee earned a total compensation of $501.1K as Chief Medical Officer at PhaseBio Pharmaceuticals, a 35% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $146,400 |
|---|---|
| Option Awards | $27,626 |
| Salary | $326,337 |
| Other | $690 |
| Total | $501,053 |
Lee received $326.3K in salary, accounting for 65% of the total pay in 2018.
Lee also received $146.4K in non-equity incentive plan, $27.6K in option awards and $690 in other compensation.
Rankings
In 2018, John Lee's compensation ranked 11,869th out of 14,244 executives tracked by ExecPay. In other words, Lee earned more than 16.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,869 out of 14,244 | 17th |
Division Manufacturing | 4,803 out of 5,759 | 17th |
Major group Chemicals And Allied Products | 1,817 out of 2,122 | 14th |
Industry group Drugs | 1,550 out of 1,811 | 14th |
Industry Pharmaceutical Preparations | 1,188 out of 1,385 | 14th |
Source: SEC filing on April 5, 2019.
Lee's colleagues
We found three more compensation records of executives who worked with John Lee at PhaseBio Pharmaceuticals in 2018.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019